460.83
price down icon1.88%   -8.82
after-market After Hours: 460.83
loading
Vertex Pharmaceuticals Inc stock is traded at $460.83, with a volume of 2.11M. It is down -1.88% in the last 24 hours and up +4.43% over the past month. Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$469.65
Open:
$467.44
24h Volume:
2.11M
Relative Volume:
1.40
Market Cap:
$118.34B
Revenue:
$11.10B
Net Income/Loss:
$-988.90M
P/E Ratio:
-117.56
EPS:
-3.92
Net Cash Flow:
$-1.26B
1W Performance:
+0.51%
1M Performance:
+4.43%
6M Performance:
+4.57%
1Y Performance:
-6.95%
1-Day Range:
Value
$460.73
$471.00
1-Week Range:
Value
$458.88
$480.00
52-Week Range:
Value
$377.85
$519.88

Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile

Name
Name
Vertex Pharmaceuticals Inc
Name
Phone
(617) 341-6393
Name
Address
50 NORTHERN AVENUE, BOSTON, MA
Name
Employee
6,100
Name
Twitter
@VertexPharma
Name
Next Earnings Date
2025-02-10
Name
Latest SEC Filings
Name
VRTX's Discussions on Twitter

Compare VRTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.83 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.63 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.79 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.19 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.51 31.54B 3.81B -644.79M -669.77M -6.24

Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-07-25 Downgrade Wolfe Research Outperform → Peer Perform
May-06-25 Downgrade Leerink Partners Outperform → Market Perform
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Feb-12-25 Upgrade Canaccord Genuity Sell → Hold
Feb-11-25 Upgrade Canaccord Genuity Sell → Hold
Jan-30-25 Downgrade Wells Fargo Overweight → Equal Weight
Dec-20-24 Reiterated H.C. Wainwright Buy
Dec-19-24 Downgrade Oppenheimer Outperform → Perform
Dec-09-24 Upgrade Jefferies Hold → Buy
Nov-14-24 Initiated Citigroup Buy
Oct-16-24 Initiated Scotiabank Sector Perform
Oct-10-24 Resumed Raymond James Mkt Perform
Aug-05-24 Downgrade Barclays Overweight → Equal Weight
Jun-27-24 Initiated Redburn Atlantic Buy
Apr-11-24 Upgrade Evercore ISI In-line → Outperform
Feb-15-24 Initiated Wolfe Research Outperform
Feb-06-24 Downgrade Evercore ISI Outperform → In-line
Feb-02-24 Downgrade Bernstein Outperform → Mkt Perform
Jan-31-24 Downgrade Maxim Group Buy → Hold
Jan-31-24 Downgrade Robert W. Baird Neutral → Underperform
Jan-24-24 Downgrade Canaccord Genuity Hold → Sell
Dec-14-23 Reiterated RBC Capital Mkts Sector Perform
May-30-23 Initiated William Blair Outperform
May-04-23 Resumed Piper Sandler Overweight
Mar-21-23 Initiated Bernstein Outperform
Jan-18-23 Initiated Canaccord Genuity Hold
Jan-17-23 Upgrade SVB Leerink Mkt Perform → Outperform
Dec-19-22 Downgrade Jefferies Buy → Hold
Jul-13-22 Initiated Cantor Fitzgerald Overweight
Jun-01-22 Upgrade Maxim Group Hold → Buy
May-23-22 Initiated SVB Leerink Mkt Perform
May-06-22 Downgrade Robert W. Baird Outperform → Neutral
May-03-22 Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-03-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jan-27-22 Reiterated JP Morgan Overweight
Jan-27-22 Reiterated Morgan Stanley Underweight
Jan-27-22 Reiterated RBC Capital Mkts Outperform
Jan-27-22 Reiterated Stifel Hold
Jan-27-22 Reiterated Wolfe Research Outperform
Jan-20-22 Upgrade BMO Capital Markets Market Perform → Outperform
Dec-09-21 Initiated Wells Fargo Overweight
Nov-19-21 Initiated BMO Capital Markets Market Perform
Nov-19-21 Downgrade Piper Sandler Overweight → Neutral
Sep-09-21 Downgrade Stifel Buy → Hold
Sep-07-21 Downgrade Morgan Stanley Equal-Weight → Underweight
Jul-20-21 Downgrade SVB Leerink Mkt Perform → Underperform
Jul-19-21 Resumed Wolfe Research Outperform
Jul-01-21 Initiated Raymond James Mkt Perform
Jun-11-21 Downgrade Daiwa Securities Outperform → Neutral
Feb-23-21 Upgrade Robert W. Baird Neutral → Outperform
Feb-02-21 Reiterated H.C. Wainwright Buy
Dec-30-20 Initiated Daiwa Securities Outperform
Nov-30-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-20-20 Initiated Bernstein Outperform
Oct-28-20 Initiated UBS Buy
Jul-31-20 Reiterated H.C. Wainwright Buy
Jul-08-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-30-20 Reiterated H.C. Wainwright Buy
Apr-28-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-04-20 Initiated Barclays Overweight
Jan-31-20 Downgrade Robert W. Baird Outperform → Neutral
Nov-19-19 Upgrade Guggenheim Neutral → Buy
Nov-12-19 Initiated SunTrust Buy
Oct-17-19 Resumed BofA/Merrill Buy
Sep-03-19 Upgrade Goldman Neutral → Buy
Aug-01-19 Downgrade Needham Buy → Hold
May-23-19 Resumed Citigroup Buy
May-21-19 Initiated Credit Suisse Outperform
Apr-12-19 Initiated Evercore ISI In-line
Mar-26-19 Upgrade William Blair Mkt Perform → Outperform
Mar-19-19 Downgrade SVB Leerink Outperform → Mkt Perform
Feb-06-19 Downgrade Maxim Group Buy → Hold
View All

Vertex Pharmaceuticals Inc Stock (VRTX) Latest News

pulisher
Jul 28, 2025

Vertex Pharmaceuticals' (VRTX) Upcoming Earnings and Strategic Momentum: A Deep Dive into Long-Term Growth Potential Amid Pipeline Advancements and Financial Resilience - AInvest

Jul 28, 2025
pulisher
Jul 28, 2025

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

How does Vertex Pharmaceuticals Incorporated generate profit in a changing economyMaximize your gains with expert trading tips - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment - MSN

Jul 28, 2025
pulisher
Jul 28, 2025

The 3 Things That Matter for Vertex Pharmaceuticals Now - AOL.com

Jul 28, 2025
pulisher
Jul 28, 2025

The 3 Things That Matter for Vertex Pharmaceuticals Now - The Motley Fool

Jul 28, 2025
pulisher
Jul 28, 2025

Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q1 Earnings? - FinancialContent

Jul 28, 2025
pulisher
Jul 27, 2025

Should I hold or sell Vertex Pharmaceuticals Incorporated stock in 2025Rapid growth opportunities - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Why is Vertex Pharmaceuticals Incorporated stock attracting strong analyst attentionInvest confidently with real-time data - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Published on: 2025-07-27 22:21:17 - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is Vertex Pharmaceuticals Incorporated a growth stock or a value stockSuperior portfolio returns - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Truist Financial Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Jul 26, 2025
pulisher
Jul 26, 2025

Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know - MSN

Jul 26, 2025
pulisher
Jul 25, 2025

Vertex Bets Big On Rare Diseases And Pain Medicine - Finimize

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Vertex Pharmaceuticals Incorporated stock priceHigh-octane financial growth - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Can Vertex Pharmaceuticals Incorporated stock recover from recent declineFree Risk Assessment Services - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Three Indian American-led firms among TIME100 Most Influential Companies - The American Bazaar

Jul 24, 2025
pulisher
Jul 23, 2025

Vertex Pharmaceuticals Incorporated Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

Vertex Pharmaceuticals (VRTX) Advances Cystic Fibrosis Treatment With ALYFTREK Approval in Canada - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Vertex Pharmaceuticals Incorporated stockFree Stock Market Return Analysis - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi - The Globe and Mail

Jul 23, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Cystic Fibrosis Pipeline Outlook 2025: Insights into Drug Development and Leading 50+ Companies - The Globe and Mail

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals: Pioneering Orphan Drug Innovation in Cystic Fibrosis and Cementing Market Leadership - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis - The Malaysian Reserve

Jul 22, 2025
pulisher
Jul 22, 2025

Is Vertex Pharmaceuticals Incorporated a good long term investmentTriple-digit wealth increases - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals (VRTX) Gets a Hold from Wells Fargo - The Globe and Mail

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need To Know - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - Yahoo Finance

Jul 22, 2025
pulisher
Jul 21, 2025

Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail

Jul 21, 2025
pulisher
Jul 21, 2025

Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace

Jul 21, 2025
pulisher
Jul 18, 2025

Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga

Jul 18, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals (VRTX): Can Strong Catalysts Propel Outperformance Ahead of Earnings? - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Lobbying Update: $1,140,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Diabetic Neuropathic Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca, Eli Lilly and Company - Barchart.com

Jul 16, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals: Strong Growth Driven by Cystic Fibrosis Success and Strategic Expansions - TipRanks

Jul 16, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals Surges to 213th in Trading Volume with $460 Million in Shares Traded Despite Stock Price Decline - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance

Jul 15, 2025

Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$558.63
price down icon 0.79%
$324.79
price down icon 1.22%
$595.19
price up icon 0.54%
biotechnology ONC
$294.51
price up icon 1.04%
$112.79
price down icon 2.19%
Cap:     |  Volume (24h):